This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
3 Primary · 27 Secondary · Reporting Duration: From randomisation (week 0) to week 240
1200 Total Participants · 2 Treatment Groups
Primary Treatment: Semaglutide · Has Placebo Group · Phase 3
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Novo Nordisk Investigational Site||100.0%|
|Did not meet criteria||50.0%|